Key result
Recombinant klotho protein reduces myocardial infarct volume ~67% following ischemia-reperfusion injury.
Why the study?
No effective therapy and potential target have been elucidated for preventing myocardial ischemia and reperfusion injury.
Does recombinant klotho protein reduce myocardial ischemia/reperfusion injury in a rat coronary artery ligation model?
Does recombinant klotho protein reduce myocardial ischemia/reperfusion injury in a rat coronary artery ligation model?
Absolute Event Rate: 5.18% vs 15.72%
p-value: p=<0.001
Recombinant klotho protein protects against myocardial ischemia/reperfusion injury by attenuating sterile inflammation and HMGB1 release in a rat model.
May attenuate experimental myocardial I/R injury in rats; hypothesis-generating with human translation untested.
Currently, no effective therapy and potential target have been elucidated for preventing myocardial ischemia and reperfusion injury (I/R). We hypothesized that the administration of recombinant klotho (rKL) protein could attenuate the sterile inflammation in peri-infarct regions by inhibiting the extracellular release of high mobility group box-1 (HMGB1). This hypothesis was examined using a rat coronary artery ligation model. Rats were divided into sham, sham+ rKL, I/R, and I/R+ rKL groups (n = 5/group). Administration of rKL protein reduced infarct volume and attenuated extracellular release of HMGB1 from peri-infarct tissue after myocardial I/R injury. The administration of rKL protein inhibited the expression of pro-inflammatory cytokines in the peri-infarct regions and significantly attenuated apoptosis and production of intracellular reactive oxygen species by myocardial I/R injury. Klotho treatment significantly reduced the increase in the levels of circulating HMGB1 in blood at 4 h after myocardial ischemia. rKL regulated the levels of inflammation-related proteins. This is the first study to suggest that exogenous administration of rKL exerts myocardial protection effects after I/R injury and provides new mechanistic insights into rKL that can provide the theoretical basis for clinical application of new adjunctive modality for critical care of acute myocardial infarction.
No takes yet. Share an insight, caveat, or question.
Myung et al. (2022) studied Myocardial ischemia/reperfusion injury (n=102). Recombinant klotho (rKL) protein vs. Saline was evaluated on Myocardial infarct volume at 4 hours (p=<0.001). Administration of recombinant klotho protein significantly reduced myocardial infarct volume to 5.18% compared to 15.72% in the control group at 4 hours after ischemia/reperfusion injury.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: